These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9169249)

  • 1. Fluoxetine discontinuation in elderly dysthymic patients.
    Devanand DP; Kim MK; Nobler MS
    Am J Geriatr Psychiatry; 1997; 5(1):83-7. PubMed ID: 9169249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
    Bogetto F; Bellino S; Revello RB; Patria L
    CNS Drugs; 2002; 16(4):273-83. PubMed ID: 11945110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder.
    Dunner DL; Schmaling KB; Hendrickson H; Becker J; Lehman A; Bea C
    Depression; 1996; 4(1):34-41. PubMed ID: 9160652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding group psychotherapy to medication treatment in dysthymia: a randomized prospective pilot study.
    Hellerstein DJ; Little SA; Samstag LW; Batchelder S; Muran JC; Fedak M; Kreditor D; Rosenthal RN; Winston A
    J Psychother Pract Res; 2001; 10(2):93-103. PubMed ID: 11264333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine withdrawal symptoms.
    Benazzi F
    Can J Psychiatry; 1996 Sep; 41(7):487. PubMed ID: 8884044
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers.
    Covi L; Hess JM; Kreiter NA; Haertzen CA
    Am J Drug Alcohol Abuse; 1995 Aug; 21(3):327-44. PubMed ID: 7484983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder.
    Devanand DP; Nobler MS; Cheng J; Turret N; Pelton GH; Roose SP; Sackeim HA
    Am J Geriatr Psychiatry; 2005 Jan; 13(1):59-68. PubMed ID: 15653941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects.
    Feige B; Voderholzer U; Riemann D; Dittmann R; Hohagen F; Berger M
    Neuropsychopharmacology; 2002 Feb; 26(2):246-58. PubMed ID: 11790520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
    Papakostas GI; Petersen T; Denninger JW; Montoya HD; Nierenberg AA; Alpert JE; Fava M
    Ann Clin Psychiatry; 2003; 15(3-4):187-92. PubMed ID: 14971864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Toxic tricyclic drug plasma level caused by fluoxetine].
    Hambrecht M
    Psychiatr Prax; 1995 Nov; 22(6):252-3. PubMed ID: 8570758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine.
    Bersani G; Meco G; Denaro A; Liberati D; Colletti C; Nicolai R; Bersani FS; Koverech A
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1219-25. PubMed ID: 23428336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open trial of fluoxetine in children and adolescents with dysthymic disorder or double depression.
    Waslick BD; Walsh BT; Greenhill LL; Eilenberg M; Capasso L; Lieber D
    J Affect Disord; 1999 Dec; 56(2-3):227-36. PubMed ID: 10701482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study.
    Zajecka J; Fawcett J; Amsterdam J; Quitkin F; Reimherr F; Rosenbaum J; Michelson D; Beasley C
    J Clin Psychopharmacol; 1998 Jun; 18(3):193-7. PubMed ID: 9617977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escitalopram versus placebo in the treatment of dysthymic disorder.
    Hellerstein DJ; Batchelder ST; Hyler S; Arnaout B; Toba C; Benga I; Gangure D
    Int Clin Psychopharmacol; 2010 May; 25(3):143-8. PubMed ID: 21811192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Citalopram in the treatment of dysthymic disorder.
    Hellerstein DJ; Batchelder S; Miozzo R; Kreditor D; Hyler S; Gangure D; Clark J
    Int Clin Psychopharmacol; 2004 May; 19(3):143-8. PubMed ID: 15107656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fluoxetine on fine motor performance in dysthymia: an 8-week, nonrandomized, open-label study.
    Schrijvers D; Maas YJ; Sabbe BG
    Clin Ther; 2009 Jan; 31(1):123-9. PubMed ID: 19243713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Anna Clark L; Thase ME; Jarrett RB
    Psychiatry Res; 2017 Jul; 253():174-181. PubMed ID: 28388454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study.
    Martenyi F; Brown EB; Caldwell CD
    J Clin Psychopharmacol; 2007 Apr; 27(2):166-70. PubMed ID: 17414240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoxetine in depressed patients on dialysis.
    Blumenfield M; Levy NB; Spinowitz B; Charytan C; Beasley CM; Dubey AK; Solomon RJ; Todd R; Goodman A; Bergstrom RF
    Int J Psychiatry Med; 1997; 27(1):71-80. PubMed ID: 9565715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
    Tohen M; Vieta E; Calabrese J; Ketter TA; Sachs G; Bowden C; Mitchell PB; Centorrino F; Risser R; Baker RW; Evans AR; Beymer K; Dube S; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2003 Nov; 60(11):1079-88. PubMed ID: 14609883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.